Forty-two adults drank pomegranate juice and plain sugar-water on separate mornings, matched calorie for calorie. Their blood sugar rose the same way both times. One gut hormone did not.
In a randomized crossover trial ↗ published September 5 in The Journal of Nutrition, the juice triggered a significantly smaller release of GIP, one of the two gut hormones that the newest obesity and diabetes drugs are built to mimic, even though the glucose curves the two drinks produced were indistinguishable.
What was measured
Each participant went through three test mornings in random order, a week apart, after sticking to a low-polyphenol background diet the whole time. On one they drank pomegranate juice, on another an equal-calorie sugar-water, on the third plain water. For two hours afterward the researchers drew blood and tracked glucose, insulin, the pancreatic hormone glucagon, and the two incretins, GLP-1 and GIP, along with C-peptide and blood fats. The volunteers were mostly healthy, averaging 33 years old, a body mass index of 27 (the low end of overweight), and normal fasting blood sugar.
Incretins are peptide hormones the gut releases when food arrives. They tell the pancreas to put out insulin and they shape how the body handles a meal. GLP-1 is the one semaglutide and the rest of the Ozempic family imitate. GIP is the second one, the extra ingredient tirzepatide adds on top of GLP-1. Because these hormones sit at the center of the metabolic drug wave, a food that moves one of them is worth a close look.
Same sugar, different hormone
On the measure most people care about, blood sugar, the two sweet drinks were a tie. Peak glucose, total glucose over the two hours, when the peak arrived and how long it lasted all came out statistically the same for pomegranate juice and sugar-water. The polyphenols the juice is marketed for, the ellagitannins and anthocyanins behind its metabolic reputation, did not blunt the sugar spike.
Where the drinks split was GIP. Pomegranate juice drove a significantly lower GIP response than sugar-water, a difference that held up after a strict statistical correction for testing many hormones at once (adjusted p equal to 0.002). GLP-1, glucagon, insulin and the rest did not separate the two drinks. So the juice changed a specific incretin signal without changing the thing that signal is usually read alongside.
That is the interesting part and also the reason to be careful. Lower GIP is easy to read as good, because GIP has been tied to fat storage and the drug field has spent years arguing over whether blocking it or boosting it is what helps. But this study measured a two-hour hormone snapshot, not weight, not insulin sensitivity, not any health outcome. A single meal that nudges one hormone down is a mechanism worth chasing, not a benefit anyone has shown.
The other finding
The researchers also ran a pattern analysis on the glucose curves themselves and found that each person's response looked more like their own response on a different day than like anyone else's (permutation p equal to 0.0002). Put plainly, individuals carry a personal glucose fingerprint that is fairly consistent from morning to morning, an idea that lines up with the growing personalized-nutrition literature and one the authors flag as exploratory rather than settled.
The limits are the usual ones for a study like this. Forty-two people, a two-hour window, a single drink, and mostly healthy volunteers whose fasting sugar was already normal. GIP was one of several hormones measured, and measuring many things raises the odds that one crosses the line by chance, which is exactly why the Bonferroni correction the authors applied matters. The trial (registered as NCT04591782) was built to compare acute responses, not to track whether a lower GIP spike adds up to anything over weeks or months.
Peptidemodel builds its cards around the receptors these hormones act on, including the GIP receptor ↗ that tirzepatide engages and the GLP-1 receptor ↗ behind semaglutide. The section has covered how a GLP-1 drug changed eating behavior at a measured meal, when GLP-1 users ate about 270 fewer calories ↗. This is the same machinery approached from the other side: not a drug turning an incretin up, but a food turning one down.